Kazia Therapeutics (Kazia Therapeutics) Days Payable

: 0.00 (As of Jun. 2023)

View and export this data going back to 1999. Start your Free Trial

Kazia Therapeutics's average Accounts Payable for the six months ended in Jun. 2023 was $1.07 Mil. Kazia Therapeutics's Cost of Goods Sold for the six months ended in Jun. 2023 was $0.00 Mil.

The historical rank and industry rank for Kazia Therapeutics's Days Payable or its related term are showing as below:

KZIA's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 147.46
* Ranked among companies with meaningful Days Payable only.

Kazia Therapeutics's Days Payable stayed the same from Jun. 2022 (0.00) to Jun. 2023 (0.00).

Kazia Therapeutics Days Payable Historical Data

The historical data trend for Kazia Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Days Payable

Kazia Therapeutics Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Days Payable																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Kazia Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kazia Therapeutics Days Payable Distribution

For the Biotechnology industry and Healthcare sector, Kazia Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Kazia Therapeutics's Days Payable falls into.

Kazia Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Kazia Therapeutics's Days Payable for the fiscal year that ended in Jun. 2023 is calculated as

	Days Payable (A: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jun. 2022 )	+	Accounts Payable (A: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2023 )	*	Days in Period
=	( (1.071	+	0.575)	/	2 )	/	0	*	365
=	0.823					/	0	*	365
=	N/A

Kazia Therapeutics's Days Payable for the quarter that ended in Jun. 2023 is calculated as:

	Days Payable (Q: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2022 )	+	Accounts Payable (Q: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
=	( (1.557	+	0.575)	/	2 )	/	0	*	365 / 2
=	1.066					/	0	*	365 / 2
=	N/A

Kazia Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Kazia Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Kazia Therapeutics (Kazia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (NAS:KZIA) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000

Website

https://www.kaziatherapeutics.com

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Executives

Josiah T Austin	director, 10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204
El Coronado Holdings, Llc	10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204